ID   WM46
AC   CVCL_6803
SY   WM-46; WM 46; WC00069
DR   cancercelllines; CVCL_6803
DR   Coriell; WC00069
DR   Cosmic; 1155269
DR   Cosmic; 1155552
DR   Cosmic; 1187582
DR   Cosmic; 1303076
DR   GEO; GSM186489
DR   GEO; GSM186490
DR   IARC_TP53; 24991
DR   Progenetix; CVCL_6803
DR   Rockland; WM46-01-0001
DR   Wikidata; Q54994306
RX   PubMed=4053039;
RX   PubMed=18632627;
RX   PubMed=18790768;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Characteristics: Highly pigmented.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=18632627; Wistar).
CC   Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Unspecified (Wistar).
CC   Omics: Transcriptome analysis by microarray.
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: D13S317: 11,13->14, D8S1179: 13,14->14 and FGA: 22,23,28->23.
CC   Discontinued: Coriell; WC00069; probable.
CC   Derived from site: Metastatic; Abdomen, skin; UBERON=UBERON_0001416.
ST   Source(s): Wistar
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 14
ST   D16S539: 11,14
ST   D18S51: 19,20
ST   D19S433: 13,14
ST   D21S11: 29,30
ST   D2S1338: 17,18
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 11
ST   D8S1179: 14
ST   FGA: 23
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 17,19
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 26
//
RX   PubMed=4053039;
RA   Herlyn M., Thurin J., Balaban G.B., Bennicelli J.L., Herlyn D.,
RA   Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H. Jr.,
RA   Koprowski H.;
RT   "Characteristics of cultured human melanocytes isolated from different
RT   stages of tumor progression.";
RL   Cancer Res. 45:5670-5676(1985).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431;
RA   Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B.,
RA   Egyhazi Brage S., Hansson J., Wu H., King A.J., Van Belle P.,
RA   Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.;
RT   "Increased cyclin D1 expression can mediate BRAF inhibitor resistance
RT   in BRAF V600E-mutated melanomas.";
RL   Mol. Cancer Ther. 7:2876-2883(2008).
//